SCHEMBL5567273

SCHEMBL5567273

CCc1cc(Cl)ccc1C(=O)OC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.48
FLT4 P35916 2/20 0.48
KDR P35968 2/20 0.48
ABL1 P00519 1/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP3A4 P08684 1/20 0.39
MAPK1 P28482 2/20 0.39
HIF1A Q16665 1/20 0.39
HSD17B1 P14061 1/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10487662 0.83 ABL1 (0.62) FLT1FLT4KDRABL1KMT2A
SCHEMBL8995796 0.81 LMNA (0.40) KMT2AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL10487630 0.81 MAPK1 (0.52) FLT1FLT4KDRKMT2AKDM4E
SCHEMBL8626368 0.81 SMN1; SMN2 (0.55) KMT2AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL10290473 0.80 HSD17B1 (0.56) FLT1FLT4KDRABL1KMT2A
SCHEMBL10487737 0.79 ALDH1A1 (0.54) FLT1FLT4KDRABL1KMT2A
SCHEMBL3089078 0.79 ALDH1A1 (0.47) KMT2AALDH1A1MEN1CYP3A4MAPK1
SCHEMBL5490646 0.78 PSMB5 (0.38) KMT2AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL1548854 0.77 SMN1; SMN2 (0.59) FLT1FLT4KDRKMT2AKDM4E
SCHEMBL7433331 0.76 CYP2A6 (0.41) ALDH1A1THRBTDP1L3MBTL1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 US disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed
US-5554617-A Method for treating cancer with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1996-09-10 US disclosed
US-5434157-A Active against herpes, hepatitis, papovavirus THE UPJOHN COMPANY (US) 1995-07-18 US disclosed
US-5002951-A 2-amino-5-halo-4-pyrimidinol for bactericides and antiprotozoa agent THE UPJOHN COMPANY (US) 1991-03-26 US disclosed
US-4665077-A IMMUNOREGULATORY AGENTS THE UPJOHN COMPANY (US) 1987-05-12 US disclosed
US-4619933-A 6-aryl pyrimidines for treating aplastic anemia THE UPJOHN COMPANY (US) 1986-10-28 US disclosed
US-4543248-A Method for immunoregulation with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1985-09-24 US disclosed
US-4507302-A Method for treating arthritis with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1985-03-26 US disclosed